A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences)
Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East)
John, T. (Department of Medical Oncology. Austin Health)
Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Goldman, J.W. (David Geffen School of Medicine. University of California)
Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences)
Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine)
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center)
Vu, H.V. (Department of Thoracic Surgery. Choray Hospital)
Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University)
Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center)
Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital)
Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine)
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS)
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS)
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto)
Zeng, L. (Late Oncology Statistics. AstraZeneca)
Hodge, R. (Late Oncology Statistics. AstraZeneca)
Atasoy, A. (Late Oncology Research and Development. AstraZeneca)
Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca)
Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)

Date:	2021
Abstract:	Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. EGFR stands for 'epidermal growth factor receptor'. It is a protein present on the surface of both healthy and cancer cells that can regulate how cells grow and divide. Sometimes, certain mutations in EGFR can result in the EGFR protein malfunctioning, which can lead to the formation of cancer, like EGFR-mutated NSCLC. Based on previous clinical studies, osimertinib is already approved for use in patients with EGFR-mutated NSCLC that has spread beyond the lung (metastatic disease). This medication works to stop, prevent, or slow the growth of EGFR-mutated NSCLC tumors, by specifically blocking the activity of EGFR. In the ADAURA clinical study, participants had resectable EGFR-mutated NSCLC, which means they had tumors that can be removed by surgery. Participants took either osimertinib or a placebo (a dummy drug with no active ingredient) after having their tumors removed by surgery. Post-surgery chemotherapy was allowed, but not compulsory (this was decided by the participant and their doctor). To date, the study has shown that osimertinib could be beneficial for patients with resectable EGFR-mutated NSCLC. Participants who took osimertinib have stayed cancer-free for longer than those who took the placebo, regardless of whether or not they received chemotherapy after surgery. Osimertinib treatment also reduced the risk of tumors spreading to the brain and spinal cord, otherwise known as the central nervous system (also called CNS). The side effects experienced by the participants taking osimertinib have been consistent with what we already know. Based on the results from ADAURA, osimertinib has been approved for the treatment of resectable EGFR-mutated NSCLC after tumor removal. The ADAURA study is still ongoing and more results are expected to be released in the future. ClinicalTrials. gov NCT number: NCT02511106.
Note:	Altres ajuts: AstraZeneca.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució i la comunicació pública de l'obra, sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835, ISSN 1744-8301

DOI: 10.2217/fon-2021-0752
PMID: 34723634

9 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles